Eric Shiozaki

Dr. Eric Shiozaki is a prominent figure in the life sciences investment sector, currently serving as a Partner at DCVC Bio, a venture capital firm focused on biotechnology and healthcare innovations. He is recognized for his expertise in identifying disruptive technologies that can significantly impact healthcare.

Professional Background

• Previous Roles: Before joining DCVC Bio, Dr. Shiozaki was a Partner at Novo Ventures, where he managed public equity strategies for small to mid-cap and late-stage biotech and medtech companies. His experience also includes serving as a Director at Apposite Capital and as an Associate at Burrill & Company. He has a solid foundation in both public and private investments, which enhances his strategic insights in venture capital.
• Education: Dr. Shiozaki has a background in structural biology and was a Leukemia & Lymphoma Society Post-Doctoral Fellow, which underscores his scientific acumen in the life sciences field.

Contributions at DCVC Bio

At DCVC Bio, Dr. Shiozaki plays a key role in strategic decision-making and business development, focusing on investments that leverage technological advancements in drug development and medical technologies. He collaborates closely with entrepreneurs to foster companies that aim to advance medicine and improve human health.123

Speaking Engagements

Dr. Shiozaki is also active in the investment community as a speaker. He has been announced as a keynote speaker for AusBioInvest 2024, where he will discuss "Investing in innovation at the intersection of technology & biology," addressing critical factors for assessing new technologies within the biotech sector.1

Summary

Dr. Eric Shiozaki's diverse experience and commitment to advancing healthcare through innovative technologies make him a significant player in the life sciences investment landscape. His work at DCVC Bio is characterized by a focus on fostering groundbreaking advancements that can lead to transformative changes in medicine and health outcomes.